Actos (pioglitazone hydrochloride) is an oral anti-diabetic drug manufactured by Takeda and prescribed to decrease blood sugar levels in patients with type 2 diabetes.

A Canada-wide settlement has been reached in five proposed class actions relating to the prescription drugs ACTOS®, APO-Pioglitazone and SANDOZ-Pioglitazone. Hearings were held in the supervising Courts in Québec and Ontario on January 27 and 28, 2021, respectively. The Courts each issued orders approving the national settlement. The settlement is now closed to new claims. The Claims Deadline for the settlement passed on November 29, 2021. For this reason we are no longer accepting new clients in these matters.